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Abstract The relationships between age-related
changes in circulating endogenous metabolites, in-
flammatory and oxidative stress markers, and arte-
rial stiffness in 57 middle-aged (34–55 years),
nonobese men were studied over the course of
3 years. Arterial stiffness was measured using
brachial-ankle pulse wave velocities (ba-PWV).
Plasma metabolomic profiling was performed using
ultra-performance liquid chromatography and quad-
rupole time-of-flight mass spectrometry. After
3 years, decreased HDL cholesterol and increased
malondialdehyde (MDA) and ox-LDL levels were
observed. Among 15 identified lipids, lysoPCs
(C16:0, C18:0, C18:2, C20:4, and C20:5) and
linoleyl carnitine were the major plasma metabo-
lites that contributed to the age-related differences.
LysoPC16:0 (variable importance in the projection
value, 6.2029) was found as the most important
plasma metabolite for evaluating these changes.
Changes in lysoPC16:0 levels positively correlated
with the changes in 8-epi-PGF2α (r00.608), MDA
(r00.413), high-sensitivity C-reactive protein (r0
0.509), IL-6 (r00.497), and ba-PWV (r00.283)
levels. ba-PWV levels positively correlated with
the changes in waist-to-hip ratios (WHR), inflam-
matory and oxidative stress markers. In a sub-
group analysis of subjects with decreased ba-
PWVs vs. increased ba-PWVs, changes in WHR
and levels of lysoPC16:0, ba-PWV, IL-6, 8-epi-
PGF2α, MDA, and P-selectin were significantly
different. Our results suggest that age-related
increases in lysoPC16:0 may contribute to lipid
peroxidation, thereby activating proinflammatory
phenotypes and arterial stiffness.
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Introduction
Aging and increased levels of circulating proinflam-
matory markers and oxidized LDLs (ox-LDLs) are
associated with arterial stiffness (Kampus et al. 2007;
Byfield et al. 2006; Brinkley et al. 2009; Scuteri et al.
2011). In particular, arterial stiffness increases with
age, even in healthy individuals without clinical car-
diovascular disease (CVD) (Zieman et al. 2005). Al-
though the exact mechanism of age-related arterial
stiffness is not fully understood, changes in numerous
endogenous metabolites in a complex physiological
aging process (Nevedomskaya et al. 2010; Yan et al.
2009) could partly result in increases of proinflamma-
tion, oxidative stress, and arterial stiffness. Particularly,
lysophosphatidylcholines (lysoPCs), proinflammatory
lipid mediators, are generated from phospholipase A2
(PLA2)-catalyzed hydrolysis of phosphatidylcholine. In
addition, lysoPCs are reported to constitute only 1–5 %
of the total PC content of non-ox-LDL; however, about
40–50 % of PC contained within LDL molecules is
converted to lysoPC during LDL oxidation (Matsumoto
et al. 2007). LysoPCs are also formed by the action of
lecithin cholesterol acyltransferase in plasma (Kougias
et al. 2006; Matsumoto et al. 2007). Recently, the in-
flammation induced by saturated or mono-unsaturated
acyl-lysoPC in vitro has been well established. There-
fore, understanding of age-related changes in these
metabolites and their relationships with inflammatory
and oxidative stress markers will allow better under-
standing of the pathological or physiological processes
underlying arterial stiffness, a condition closely associ-
ated with aging.
Accordingly, to study the relationship of age-
related changes in the levels of endogenous metabo-
lites and inflammatory and oxidative stress markers
with arterial stiffness, we observed 57 nonobese
men between the ages of 34 and 55 years, without
a disease history for 3 years. To compare age-
related changes between the baseline and 3-year
follow-up data, we used a metabolomics approach
based on the combination of ultra-performance liq-
uid chromatography and quadrupole time-of-flight
mass spectrometry (UPLC-Q-TOF MS) coupled
with multivariate data analyses. Additionally, to
analyze the oxidative and inflammatory status of
the study subjects at baseline and after 3 years, we
measured the levels of inflammatory and oxidative
markers using specific immunoassays and mea-




The study protocol was approved by the Institu-
tional Review Board of the National Health Insur-
ance Corporation (NHIC)-sponsored Ilsan Hospital,
Korea, and was conducted in accordance with the
Helsinki Declaration. Fifty-seven healthy, nonobese
male subjects (20≤body mass index (BMI)<30 kg/
m2) between the ages of 34–55 years visiting a
health promotion center at the NHIC-sponsored
Ilsan Hospital in Korea between August 2007
and October 2007 were enrolled in this study.
The subjects led a sedentary lifestyle and had not
participated in weight reduction programs within
the previous 3 years. The subjects also completed
a personal health and medical history questionnaire
that served as a screening tool for enrollment.
Exclusion criteria included the presence of type 2
diabetes, CVD, or psychiatric problems, or the use
of anti-hypertensive, lipid-lowering, anti-platelet,
or anti-diabetic medications. The duration of the
study was 3 years. At baseline, the usual dietary
intake of the study subjects was assessed using a
semiquantitative food frequency questionnaire and
a 24-h recall method. The subjects were encour-
aged to maintain their body weight within ±3 kg
and were given general oral and written informa-
tion about healthy food choices and exercise at
baseline and at the subsequent visit (week 4).
The subjects were instructed by trained dietitians
and were also asked to keep 3-day food records (2
weekdays and 1 weekend) at each visit. Nutrient
intake was determined and calculated based on the
3-day food records using the Computer-Aided Nu-
tritional Analysis Program (CAN-pro 2.0; Korean
Nutrition Society, Seoul, Korea). Total energy ex-
penditure (TEE) (kcal/day) was calculated based
on the activity patterns of the study subjects, such
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as basal metabolic rate, 24-h physical activity, and
specific dynamic actions of food.
Anthropometric parameters, blood pressure, and blood
collection
Body weights and heights were measured in the
morning while the study subjects were unclothed
and without shoes. BMI (kg/m2) was calculated
based on body weight and height. Percent body
fat was analyzed using a TBF-105 body fat ana-
lyzer (Tanita Co., Tokyo, Japan). Waist circumfer-
ence was measured at the umbilical level, with the
subjects standing after normal expiration. Blood
pressure (BP) was measured in the left arm of
seated patients using an automatic blood pressure
monitor (TM-2654, A&D, Tokyo, Japan) after a
20-min rest period. After a 12-h fast, venous blood
specimens were collected in EDTA-treated or un-
treated tubes. Plasma or sera were separated and
stored at −70 °C until further analysis.
Serum lipid profiles and fasting glucose levels, insulin
concentrations, and homeostasis model assessment
for insulin resistance
Fasting total cholesterol and triglyceride levels
were measured using commercially available kits
and a Hitachi 7150 autoanalyzer (Hitachi Ltd.,
Tokyo, Japan). After precipitation of serum chylo-
microns using dextran sulfate magnesium, HDL
cholesterol concentrations in the supernatants were
enzymatically measured. For subjects with serum
triglyceride levels <400 mg/dL, LDL cholesterol
levels were estimated directly using the Friedwald
formula: LDL cholesterol 0 total cholesterol−
(HDL cholesterol + [triglycerides/5]). For subjects
with serum triglyceride levels ≥400 mg/dL, LDL
cholesterol levels were measured indirectly. Fasting
glucose levels were measured by the glucose oxi-
dase method using a Beckman glucose analyzer
(Beckman Instruments, Irvine, CA, USA). Insulin
levels were measured by radioimmunoassay using
a commercial kit (Immuno Nucleo Corporation,
Stillwater, MN, USA). Insulin resistance (IR) was
calculated based on the homeostasis model assess-
ment (HOMA) using the following equation:
HOMA-IR 0 (fasting insulin [μIU/mL] × fasting
glucose [mmol/L])/22.5.
Measurement of serum IL-6 levels, serum high-
sensitivity C-reactive protein levels, white blood cell
counts, and urinary 8-epi-PGF2α levels
Serum interleukin (IL)-6 concentrations were measured
using Bio-Plex™Reagent Kits and a Bio-Plex™ system
(Bio-Rad Laboratories, Hercules, CA, USA) according
to the manufacturer’s instructions. The high-sensitivity
C-reactive protein (hs-CRP) levels were measured on an
Express Plus™ auto-analyzer (Chiron Diagnostics Co.,
Walpole, MA, USA) using commercially available
high-sensitivity CRP-Latex (II) X2 kits (Seiken Labora-
tories Ltd., Tokyo, Japan). White blood cell (WBC)
counts were determined using a hematology analyzer
from HORIBA ABX Diagnostic (HORIBA ABX SAS,
Parc Euromedicine, France). The compound 8-epi-
PGF2α was measured using an enzyme immunoassay
(BIOXYTECH urinary 8-epi-PGF2αTM Assay kit,
OXIS International Inc., Portland, OR, USA). Urinary
creatinine levels were determined using the alkaline
picrate (Jaffe) reaction.
Plasma-oxidized LDL, adiponectin, malondialdehyde,
sVCAM-1, sICAM-1, and P-selectin levels
Plasma-oxidized (ox) LDL levels were measured using
an enzyme immunoassay (Mercodia, Uppsala, Sweden).
Plasma adiponectin concentrations were measured us-
ing an enzyme immunoassay (Human Adiponectin
ELISA kit, B-Bridge International Inc., CA, USA).
The absorbencies of the resulting color reactions (ox-
LDLs and adiponectin) were measured at a wavelength
of 450 nm using a Wallac Victor2 multilabel counter
(Perkin Elmer Life Sciences, Turku, Finland). The
wavelength correction was set to 540 nm. Plasma
malondialdehyde (MDA) concentrationsweremeasured
based on the production of thiobarbituric acid-reactive
substances (TBARS Assay Kit, Zepto-Metrix Co., Buf-
falo, NY, USA). Plasma vascular cell adhesionmolecule
(VCAM)-1, inter-cellular adhesionmolecule (ICAM)-1,
and P-selectin levels were measured using Bio-Plex™
Reagent Kits with a Bio-Plex™ system (Bio-Rad)
according to the manufacturer’s instructions.
Brachial-ankle pulse wave velocity measurement
ba-PWVs were measured using an automatic wave-
form analyzer (model VP-1000; Nippon Colin Ltd.,
Komaki, Japan) according to a previously described
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method (Kim et al. 2010a, b). The average ba-PWV
from both left and right sides was used for analysis
(correlation between the right and left ba-PWVs: r20
0.925, P<0.001).
Plasma metabolic profiling
Plasma samples were prepared and injected into a
UPLC/Q-TOF MS (Waters, Milford, MA, USA)
according to previously described methods (Kim
et al. 2010a, b). The Q-TOF MS was operated in
positive electrospray ionization (ESI) mode. The
capillary and sampling cone voltages were set at
2.78 kV and 26 V, respectively. The desolvation
flow was set to 700 L/h at 300 °C, and the source
temperature was set to 110 °C. The TOF MS data
were collected in the range of 50–1000m/z, with a
scan time of 0.2 s and interscan delay time of
0.02 s. All analyses were performed using lock
spray to ensure accuracy and reproducibility;
leucine-enkephalin (556.2771 Da in the positive
ESI mode) was used as the lock mass at 200 pmol
and a flow rate of 3 μL/min. The lock spray
frequency was set at 10 s.
For quality control, a mixture of five standard
compounds (caffeine, sulfadimethoxine, terfena-
dine, 4-acetoaminophenol, and reserpine) was
injected after every seven samples. The MS/MS
spectra of the metabolites were obtained by a
collision energy ramp from 10 to 30 eV. Accurate
masses and compositions of the precursor and
fragment ions were calculated and sequenced using
MassLynx 4.1 software (Waters) incorporated in
the instrument. All MS data, including retention
time, m/z, and ion intensity, were extracted using
the MarkerLynx 4.1 software package (Waters)
incorporated in the instrument, and the resulting
MS data were assembled into a data matrix.
Peaks were collected using a peak width of
5 %, a height of 1 s, a noise elimination of 6,
and an intensity threshold of 120. Data were
aligned with a mass tolerance of 0.04 Da and a
retention time window of 0.15 min. All spectra
were aligned and normalized to the total peak
intensity. Assignment of metabolites contributing
to the observed variance was performed using the
elemental composition analysis software using cal-
culated mass, mass tolerance (mDa and ppm),
double-bond equivalent, and the i-Fit algorithm
(the likelihood that the isotopic pattern of the
elemental composition matches a cluster of peaks
in the spectrum) implemented in the MassLynx
software by the ChemSpider database (www.
chemspider.com) and by the Human Metabolome
Database (www.hmdb.ca). Authentic standards
were used to confirm the assignments and to per-
form quantitative analyses.
Statistical analysis
Statistical analyses were performed using SPSS
ver12.0 (Statistical Package for the Social Scien-
ces, SPSS Inc., Chicago, IL, USA). The skewed
variables were logarithmically transformed for sta-
tistical analysis. For descriptive purposes, mean
values were presented using untransformed val-
ues. Results are expressed as means ± standard
error (SE). A two-tailed P value of <0.05 was
considered as statistically significant. Paired t-
tests and Wilcoxon signed-rank tests were used
to evaluate differences between baseline and 3-
year follow-up levels. Differences in the clinical
variables between the decreased ba-PWV and in-
creased ba-PWV groups were tested by indepen-
dent t-tests and Mann–Whitney U-tests. General
linear model tests (mixed model tests) were ap-
plied to the comparison of the changes in varia-
bles over time by adjusting for confounding
factors. Pearson’s and partial correlation coeffi-
cients were used to examine the relationships
between variables over time.
Multivariate statistical analysis was performed
using SIMCA-P+ software version 12.0 (Umetrics,
Umeå, Sweden). Partial least-squares discriminant
analysis (PLS-DA) was used as the classification
method for modeling discrimination between the
baseline and 3-year follow-up data by visualizing
score plots or S-plots using the first and second
PLS components. To validate the model, a seven-
fold validation was applied to the PLS-DA model,
and the reliabilities of the model were further
rigorously validated by a permutation test (n0
200). Goodness of fit was quantified by R2Y,
while the predictive ability was indicated by Q2Y.
Generally, R2Y, which describes how well the data
in the training set are mathematically reproduced,
varies between 0 and 1, with 1 indicating a model
with a perfect fit.
1510 AGE (2013) 35:1507–1519
Results
Clinical characteristics, inflammatory markers, arterial
stiffness, lipid peroxides, adhesion molecules,
and nutrient intakes at baseline and at 3-year follow-up
After 3 years, the subjects showed decreased levels of
HDL cholesterol (P<0.001) and increased levels of
MDA (P<0.001) and ox-LDLs (P<0.001) (Table 1).
There were no significant differences in the levels of
inflammatory markers, arterial stiffness, and adhesion
molecules between the baseline and 3-year follow-up
data. The estimated total calorie intake at baseline was
2,441±27 kcal/day and at 3-years follow-up was
2,429±23 kcal/day. There were no statistically signif-
icant differences in macronutrient intakes, especially
polyunsaturated/monounsaturated/saturated (P/M/S)
fat intake ratio between the baseline (1:0.96:0.72)
and the 3-year follow-up (1:1.01:0.74) data. Also,
there were no significant differences in total energy
expenditure and the proportions of smoking and
drinking between the baseline and the 3-year follow-
up data (data not shown).
Multivariate statistical analysis and identification
of plasma metabolites
The MS data of plasma metabolites obtained from
healthy men at baseline and at 3-year follow-up were
applied to a PLS-DA score plot (Fig. 1a). The first
two-component PLS-DA score plots of the plasma
metabolites showed distinct clustering for each group
of healthy men at baseline and at 3-year follow-up.
Both groups could be clearly differentiated from each
other by the primary component t(1) or the secondary
component t(2) based on the model with R2X (cum)
and R2Y (cum) values of 0.391 and 0.990, respective-
ly, indicating the goodness of fit of the data. The Q2Y
(cum) value of 0.818 estimated the predictive ability
of the model. In addition, the PLS-DA models were
validated using a permutation test and indicated an
R2Y intercept value of 0.0971 and a Q2Y intercept
Table 1 Clinical characteristics,
inflammatory markers, brachial-
ankle pulse wave velocity, lipid
peroxides, and adhesion mole-
cules at baseline and at the 3-
year follow-up
P-values derived from paired t-
test with the Wilcoxon signed-
rank test
HOMA-IR {fasting insulin (μIU/
mL) × fasting glucose (mmol/
L)}/22.5
aMean ± SE tested by logarith-
mic transformation
Baseline 3-year follow-up P
Age (year) 45.3±0.88 48.1±0.89 <0.001
Body mass index (kg/m2) 24.6±0.32 24.6±0.29 0.953
Waist-to-hip ratio 0.90±0.01 0.91±0.01 0.267
Systolic BP (mmHg) 120.1±1.50 120.8±1.99 0.940
Diastolic BP (mmHg) 74.9±1.35 75.2±1.60 0.954
Triglyceride (mg/dL)a 137.8±10.7 138.8±10.7 0.953
Total cholesterol (mg/dL)a 192.4±4.61 190.3±4.31 0.987
HDL cholesterol (mg/dL)a 51.5±1.87 45.3±1.50 <0.001
LDL cholesterol (mg/dL)a 114.9±4.73 118.8±3.95 0.119
Glucose (mg/dL)a 93.9±1.55 96.0±1.72 0.117
Insulin (μU/mL)a 8.34±0.43 8.04±0.48 0.581
HOMA-IRa 1.94±0.11 1.90±0.12 0.946
hs-CRP (mg/L)a 1.23±0.25 0.84±0.08 0.941
Serum IL-6 (pg/mL)a 4.83±0.50 4.17±0.46 0.130
White blood cells (×109/L)a 6.16±0.31 5.77±0.17 0.639
Adiponectin (μg/mL)a 5.27±0.31 5.39±0.27 0.224
ba-PWV (cm/s)a 1,340.3±27.5 1,357.2±29.5 0.264
8-epi-PGF2α (pg/mg creatinine)
a 1,353.8±73.7 1,384.6±67.5 0.838
Malondialdehyde (nmol/mL)a 9.92±0.31 12.4±0.47 <0.001
Oxidized LDL (U/L)a 34.0±1.46 43.0±1.89 <0.001
sICAM-1 (pg/mL) 193.3±7.65 193.5±9.38 0.658
sVCAM-1 (pg/mL) 676.5±46.9 749.7±65.4 0.043
P-selectin (pg/mL) 33.9±1.65 37.1±2.20 0.153
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value of 0.0113. To identify the metabolites contribut-
ing to the discrimination between the baseline and the
3-year follow-up data, S-plots of p(1) and p(corr)(1)
were generated using centroid scaling (Fig. 1b). The S-
plots revealed that the metabolites with higher or
lower p(corr) values served as the more relevant ions
for discriminating between the two groups.
Among the 813 metabolites in the plasma, the metab-
olites that play an important role in determining age-
related changes after the 3-year follow-up were selected
according to their variable importance in the projection
(VIP) scores. The normalized intensities of whole metab-
olites were statistically analyzed by a nonparametric
t-test; the metabolites with significant differences be-
tween the baseline and 3-year follow-up data were in-
cluded. Thus, 17 metabolites were selected based on their
VIP values and independent t-tests. Finally, 15 metabo-
lites were identified (two were unknown). The results of
the UPLC-Q-TOF analysis are shown in Table 2.
Eight plasma metabolites, including L-valine, lyso-
phosphatidyl cholines (lysoPCs) containing C16:0,
C18:2, C20:4, C20:5, C22:5, and C22:6, and lysophos-
phatidyl ethanolamines (lysoPEs) containing C18:0 and
C22:6, showed significant increases at 3-year follow-up,
whereas three metabolites, including pyrroline hydrox-
ycarboxylic acid, linoleyl carnitine, and total lysoPCs,
showed decreased levels. Linoleyl carnitine and
lysoPCs containing C16:0, C18:0, C18:2, C20:4, and
C20:5 (with VIP values >1.0, indicating a high rele-































Fig. 1 a Score plots from
PLS-DA models classifying
healthy men at baseline
(filled square) and at 3-year
follow-up (filled triangle). b
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the major plasma metabolites contributing to the dis-
crimination between the baseline and 3-year follow-up
data on the PLS-DA score plot (Table 2). In particular,
lysoPC 16:0 with a VIP value of 6.2029 served as the
most important plasma metabolite for evaluating the
differences between the baseline and 3-year follow-up
data.
Relationship between the changes in the major plasma
metabolite levels
The changes in lysoPC 16:0 levels were positively
correlated with the changes in lysoPC 18:0 (r00.624,
P<0.001), lysoPC 18:2 (r00.620, P<0.001), and
lysoPC 20:5 (r00.414, P00.003) levels. The changes
in lysoPC 18:0 were positively correlated with the
changes in lysoPC 18:2 (r00.773, P<0.001) and
lysoPC 20:5 (r00.600, P<0.001). The changes in
lysoPC 18:2 were positively correlated with the
changes in lysoPC 20:4 (r00.325, P00.023) and
lysoPC 20:5 (r00.395, P00.005). The changes in
linoleyl carnitine were positively correlated with the
changes in pyrroline hydroxycarboxylic acid (r0
0.464, P00.001).
Relationship between the changes in levels of lysoPC
16:0, arterial stiffness, lipid peroxides, inflammatory
markers, and adhesion molecules
The changes in lysoPC 16:0 between the baseline and
3-year follow-up data were positively correlated with
the changes in 8-epi-PGF2α (r00.608, P<0.001)
(Fig. 2), MDA (r00.413, P00.004), hs-CRP (r0
0.509, P<0.001) (Fig. 2), IL-6 (r00.497, P00.001),
and ba-PWV (r00.283, P00.049). Additionally, de-
creased HDL cholesterol was significantly associated
with increased levels of lysoPC 20:5 (r0−0.286, P0
0.049) and lysoPC 22:6 (r0−0.422, P00.003) among
the 15 endogenous metabolites, which were main-
tained after adjusting for changed values of age,
BMI, LDL cholesterol, and triglyceride (r0−0.295,
P00.052; r0−0.466, P00.001, respectively). The
changes in ba-PWV were positively correlated with
the changes in waist-to-hip ratio (WHR) (r00.329, P0













L-Valine C5H11NO2 118.0789 −6.0 13.0±0.45 15.3±0.53 1.140 0.001 0.2058
Pyrroline hydroxycarboxylic acid C5H7NO3 130.0425 −6.4 3.30±0.10 2.54±0.10 0.737 <0.001 0.2809
L−Tryptophan C11H12N2O2 205.0898 −7.6 32.1±1.56 31.4±1.64 0.944 0.704 0.8036
Linoleyl carnitine C25H45NO4 424.3348 −4.4 25.6±1.09 21.9±1.29 0.845 0.009 1.4369
LysoPC (16:0) C24H50NO7P 496.3324 −6.0 718.7±16.2 778.1±27.1 1.064 0.028 6.2029
LysoPC (18:0) C26H54NO7P 524.3637 −6.2 545.9±15.0 574.0±17.0 1.043 0.231 4.6709
LysoPC (18:2) C26H50NO7P 520.3325 −5.9 467.8±11.4 510.6±14.4 1.081 0.004 4.6890
LysoPC (18:3) C26H48NO7P 518.3168 −6.2 12.5±0.66 14.8±0.98 1.152 0.068 0.4923
LysoPC (20:4) C28H50NO7P 544.3325 2.5 54.7±3.56 66.1±6.38 1.175 0.021 1.4186
LysoPC (20:5) C28H48NO7P 542.3168 −0.7 39.1±1.52 45.4±1.32 1.134 0.002 1.1194
LysoPC (22:5) C30H52NO7P 570.3481 −8.3 1.88±0.18 2.56±0.22 1.272 0.002 0.0565
LysoPC (22:6) C30H50NO7P 568.3325 3.6 48.3±1.36 53.0±1.16 1.083 0.007 0.5201
LysoPE (18:0) C23H48NO7P 482.3168 −7.4 8.88±0.50 10.7±0.43 1.176 0.004 0.2748
LysoPE (22:6) C27H44NO7P 526.2855 −5.8 28.1±0.77 31.5±0.98 1.107 0.003 0.5602
Total LysoPC – – – 8.59±1.23 6.51±0.83 0.713 0.001 –
Unknown 1 – 417.3290 −7.3 – – 0.100 – 0.5015
Unknown 2 – 585.2634 −8.5 – - 1.720 - 0.5597
aMean ± SE calculated by the mean of intensity of each metabolite from cases by the mean of intensity of each metabolite from controls
bP-values derived from paired t-test with the Wilcoxon signed-rank test
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0.012) (Fig. 2), ox-LDLs (r00.312, P00.023), MDA
(r00.302, P00.024), hs-CRP (r00.329, P00.013),
IL-6 (r00.298, P00.038) (Fig. 2), and P-selectin (r0
0.345, P00.034). The changes in hs-CRP were posi-
tively correlated with the changes in 8-epi-PGF2α (r0
0.541, P<0.001) (Fig. 2), ox-LDLs (r00.296, P0
0.033), and IL-6 (r00.635, P<0.001). Additionally
the changes in IL-6 were also positively correlated
with the changes in WHR (r00.287, P00.046) and
8-epi-PGF2α (r00.311, P00.031). Furthermore, the
ratio of total calorie intake to total calorie expenditure
(TCI/TEE) was closely related with the changes in
WHR (r00.450, P<0.001).
Association of the levels of inflammatory markers,
lipid peroxides, adhesion molecules, and metabolites
with the changes in arterial stiffness
Because of the close relationship between the changes
in levels of lysoPC 16:0, arterial stiffness, lipid per-
oxides, inflammatory markers, and adhesion mole-
cules, we divided our subjects into two groups
according to the changes in arterial stiffness from
baseline to 3-year follow-up (decreased ba-PWV vs.
increased ba-PWV groups). As ba-PWV was highly
associated with blood pressure (systolic and diastolic),
we adjusted for blood pressure when we compared the
values between the groups. At baseline, men in the
increased ba-PWV group (n030) had lower hs-CRP
levels (P00.039) than those in the decreased ba-PWV
group had. After 3 years, men in the decreased ba-
PWV group (n027) showed a significant reduction in
ba-PWVs (P<0.001) and serum IL-6 (P00.038) levels
and significant increases in the levels of MDA (P0
0.032) and ox-LDLs (P00.009) (Table 3). Men in the
increased ba-PWV group showed significant increases
in WHR (P00.025) and levels of ba-PWV (P<0.001),
MDA (P<0.001), ox-LDLs (P00.002), and P-selectin
(P00.002) after 3 years. In addition, the changes in
WHR (P00.043), ba-PWV (P<0.001), IL-6 (P0
0.038), 8-epi-PGF2α (P00.004), MDA (P00.027),
and P-selectin (P00.004) levels were significantly
different between the two ba-PWV groups after ad-
justment for changes of blood pressure (Table 3). Ad-
ditionally, changes in lysoPC 16:0 levels were
significantly different between the decreased and in-
creased ba-PWV groups (−14.7±50.7 vs. 106.4±29.5;
P00.049) after the adjustment. There were no signif-
icant changes in other plasma metabolite levels
between the ba-PWV groups before or after adjust-
ment for baseline values (data not shown).
Discussion
Using a metabolomics approach based on UPLC/Q-
TOF MS, we identified 15 endogenous metabolites
that showed age-related changes in middle-aged men.
Among these metabolites, lysoPCs containing C16:0,
C18:0, C18:2, C20:4, and C20:5 and linoleyl carnitine
were the six major metabolites contributing to the
discrimination between the baseline and 3-year
follow-up. Various species of lysoPC are defined by
fatty acid chain length and degree of saturation, which
may translate into different physical and biological
properties (Loftus et al. 2008). Although lysoPC levels
obviously increase in aging rats (Fu et al. 2011), this
important issue is largely unexplored in humans. In
our study, among the six major metabolites identified
by mass spectrometric analysis, lysoPC 16:0 was
found to be the most important plasma metabolite for
evaluating aging-related changes. Additionally, the
changes in lysoPC 16:0 levels were strongly positively
correlated with the changes in levels of 8-epi-PGF2α, a
reliable marker of oxidative stress (Wolfram et al.
2005; Vassalle et al. 2004), MDA, hs-CRP, IL-6, and
ba-PWVs. This result suggests that age-related
changes in lysoPC 16:0 levels in middle-aged men
could contribute to lipid peroxidation, the activation
of a proinflammatory phenotype, and arterial stiffness.
Furthermore, increases in lysoPC 16:0 levels from the
baseline to the 3-year follow-up data were significant-
ly greater in subjects with increased ba-PWVs. Pulse
wave velocity is an established index of arterial stiff-
ness (Tomiyama and Yamashina 2010), and ba-PWVs
show similar characteristics to those of central aortic
PWV (Tsuchikura et al. 2010).
Arterial stiffness, one of the most significant man-
ifestations of vascular aging (Lakatta and Levy 2003;
Lakatta 2003), can result in increased systolic blood
pressure (Dao et al. 2005; O’Rourke and Hashimoto
2007). This is a condition that can worsen with age,
even in healthy individuals without CVD. In addition,
the presence of CVD risk factors such as obesity may
accelerate the vascular changes that result in arterial
stiffness (Zieman et al. 2005). However, in our study,
we did not find significant changes overall in ba-PWV
and WHR in subjects during the 3-year follow-up.

















r=0.608 p<0.001 r=0.509 p<0.001
r=0.329 p=0.012 r=0.298 p=0.038
Fig. 2 Relationship of the changes in lysoPC (16:0) levels, WHR, and IL-6 with the changes in 8-epi-PGF2α, CRP, and ba-PWV in
healthy men after 3 years. Tested by Pearson correlation analysis. r, correlation coefficient
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Table 3 Inflammatory markers, lipid peroxides, and adhesion molecules according to changes in arterial stiffness at baseline and at
3-year follow-up
Controls (PWV decreased) (n027) Pa Cases (PWV increased) (n030) Pa Pb
Body mass index (kg/m2)
Baseline 23.9±0.47 0.343 25.3±0.41 0.251 0.094
Follow-up 24.1±0.35 25.1±0.44 0.235
Change 0.16±0.27 −0.16±0.13 0.194
Waist-to-hip ratio
Baseline 0.91±0.01 0.592 0.89±0.01 0.025 0.247
Follow-up 0.90±0.01 0.91±0.01 0.332
Change −0.01±0.01 0.02±0.01 0.043
ba-PWV (cm/s)
Baselinea 1,385.9±49.7 <0.001 1,299.3±25.4 <0.001 0.096
Follow-upa 1,306.1±50.6 1,403.3±31.4 0.118
Change −79.9±13.7 104.0±13.0 <0.001
White blood cells (×109/L)
Baselinea 6.71±0.56 0.038 5.67±0.29 0.508 0.088
Follow-upa 5.74±0.25 5.81±0.24 0.909
Change −0.97±0.50 0.14±0.26 0.043
hs-CRP (mg/L)
Baselinea 1.84±0.51 0.039 0.71±0.11 0.040 0.005
Follow-upa 0.73±0.09 0.94±0.13 0.617
Change −1.11±0.53 0.23±0.17 0.007
Serum IL-6 (pg/mL)
Baselinea 5.40±0.82 0.038 4.28±0.60 0.757 0.301
Follow-upa 3.37±0.43 4.94±0.78 0.226
Change −2.03±1.01 0.67±0.57 0.038
8-epi-PGF2α (pg/mg creatinine)
Baselinea 1,307.0±111.1 0.399 1,394.5±99.6 0.039 0.985
Follow-upa 1,182.9±73.1 1,559.4±99.3 0.003
Change −124.1±115.6 164.9±144.0 0.027
MDA (nmol/mL)
Baselinea 10.2±0.46 0.032 9.68±0.42 <0.001 0.292
Follow-upa 11.6±0.55 13.1±0.72 0.165
Change 1.42±0.54 3.46±0.67 0.027
Oxidized LDL (U/L)
Baselinea 33.6±2.08 0.009 34.3±2.08 0.002 0.951
Follow-upa 41.4±2.07 44.7±3.21 0.954
Change 7.81±2.66 10.4±2.60 0.788
sICAM-1 (pg/mL)
Baseline 181.7±10.6 0.526 201.7±10.6 0.676 0.290
Follow-up 187.6±15.2 197.8±12.1 0.615
Change 5.91±10.7 −3.96±5.81 0.555
sVCAM-1 (pg/mL)
Baseline 698.6±74.4 0.335 660.5±61.5 0.138 0.455
Follow-up 755.5±104.5 745.6±85.8 0.829
Change 56.9±66.8 85.1±65.4 0.659
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When we subdivided study subjects according to the
changed levels of ba-PWV, we found interesting
results. Men in the subgroup of increased ba-PWVs
showed significant increases in abdominal obesity,
which were correlated with increases in IL-6 and the
ratio of TCI/TEE (the ratio of total calorie intake to
total calorie expenditure). Additionally, changes in
WHR, MDA, hs-CRP, IL-6, 8-epi-PGF2α, and P-
selectin levels were significantly different between
subjects with decreased and increased ba-PWVs.
However, the changes in MDA together with those
in ox-LDL were in the same direction in both ba-PWV
sub-groups (increased in both) which may need to be
further studied as to whether this phenomenon occurs
independent of ba-PWV change or not. Actually, the
mechanisms underlying arterial stiffening remain to be
elucidated, but the fact that changes in ba-PWV be-
tween the baseline and 3-year follow-up data were
positively correlated with the changes in WHR, ox-
LDLs, MDA, hs-CRP, and IL-6 levels suggest that
changes in oxidative stress, proinflammation, or ab-
dominal obesity could play an important role, in part,
in accelerating arterial stiffness. Recently, Brinkley et
al. (2009) suggested that ox-LDL levels may be relat-
ed to the pathogenesis of arterial stiffness, independent
of other CVD risk factors.
LysoPC constitutes only 1–5 % of the total PC con-
tent of non-ox-LDL; however, as much as 40–50 % of
the PC contained within the LDL molecule is converted
to lysoPC during LDL oxidation (Matsumoto et al.
2007). A saturated fatty acid or a monounsaturated fatty
acid predominates in the sn-1 position of the phospho-
lipid (Stafforini et al. 2006). The generation of free
radicals as a result of oxidative stress can activate phos-
pholipase A2 (PLA2), which hydrolyzes phosphatidyl-
choline (PC) to produce lysoPCs (Steinbrecher and
Pritchard 1989). Production of α-palmitoyl-lysoPC
(C16:0) can stimulate endothelial cells to express adhe-
sion molecules and release cytokines (Takabe et al.
2004; Kume et al. 1992; Murohara et al. 1996; Zhu et
al. 1997; Liu-Wu et al. 1998; Rong et al. 2002). In fact,
IL-6 was found to be induced by α-palmitoyl-lysoPC
treatment in human umbilical vein endothelial cells. In
line with this result, our study showed a significant age-
related increase in both ox-LDL and lysoPC 16:0 levels
and a positive relationship between the changes in
lysoPC 16:0 and IL-6 levels.
PLA2, including secretory PLA2 (sPLA2) and
lipoprotein-associated phospholipase (Lp-PLA2),
hydrolyzes PC, simultaneously generating one molecule
of lysoPC and one molecule of arachidonic acid, a
precursor of eicosanoids such as prostaglandins and
leukotrienes (Matsumoto et al. 2007). Radical peroxida-
tion of arachidonic acid results in a family prostaglandin
F2-isomers called F2 isoprostanes (Voss and Siem 2006).
One such F2-isoprostane is 8-epi-PGF2α, a sensitive
marker for oxidative stress (Wolfram et al. 2005;
Vassalle et al. 2004) that is probably released into biolog-
ical fluids through a phospholipase-mediated pathway
and consequently excreted in urine. In this study, changes
in lysoPC 16:0 were closely and positively associated
with changes in urinary 8-epi-PGF2α concentrations.
Additionally, changes in lysoPC 16:0 and 8-epi-PGF2α
were closely related with changes in CRP concentrations.
LysoPCs, representing 5–20 % of the total plasma
phospholipids (Nelson 1967), are also formed by the
action of lecithin cholesterol acyltransferase (LCAT)
in plasma (Kougias et al. 2006). Human LCAT
releases lysoPC 20:4 and 22:6 from the sn-1 position
of PC (Liu et al. 1998). In plasma, up to 80 % of the
lysoPC is found in the non-lipoprotein fraction, in
which albumin is considered to be the main lipid-
Table 3 (continued)
Controls (PWV decreased) (n027) Pa Cases (PWV increased) (n030) Pa Pb
P-selectin (pg/mL)
Baseline 36.3±2.92 0.342 32.2±1.87 0.002 0.188
Follow-up 33.8±3.06 39.5±3.04 0.183
Change −2.53±2.34 7.33±2.67 0.004
aMean ± SE tested by logarithmic transformation. Tested by general linear model tests (mixed model tests) with adjustment
aP-values within a group derived after adjusting for changed SBP and DBP
bP-values between groups derived after adjusting for changed SBP and DBP
ba-PWV brachial-ankle pulse wave velocity, MDA malondialdehyde
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binding protein (Ojala et al. 2006). Unsaturated
lysoPCs are mainly associated with albumin rather
than lipoproteins (Croset et al. 2000). In our study,
we observed a positive relationship between the
changes in levels of lysoPC 16:0 and those of lysoPCs
containing C18:0, C18:2, and C20:5, which could
reflect an alternative source of lysoPC C16:0 produc-
tion in addition to ox-LDLs.
In our study, a large number of metabolite markers
were detected by UPLC-MS; however, most of these
metabolite markers remain unidentified. Unlike gas
chromatography–mass spectrometry, for which large
databases exist, the use of liquid chromatography–
mass spectrometry-based techniques for metabolomics
research is still in its infancy, and the databases of
endogenous biomolecules have not yet been con-
structed (Williams et al. 2006). Despite this limitation,
using a UPLC-Q-TOF MS-based metabolomics strat-
egy and multivariate data analysis, our study identified
a cluster of age-associated changes in plasma metab-
olites that included six major metabolites: lysoPCs
containing C16:0, C18:0, C18:2, C20:4, and C20:5
and linoleyl carnitine. Among these six major metab-
olites, lysoPC 16:0 served as the most important plas-
ma metabolite for evaluating age-related differences
between the baseline and 3-year follow-up data. Ad-
ditionally, the changes in lysoPC 16:0 levels were
positively correlated with the changes in levels of lipid
peroxides, proinflammatory markers, and ba-PWV.
These results suggest that increases in lysoPC 16:0
can be explored further as a potential marker for lipid
peroxidation, the activation of a proinflammatory phe-
notype, and arterial stiffness related to aging.
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